| Prev Close | 52.13 |
| Open | 52.14 |
| Day Low/High | 51.48 / 52.83 |
| 52 Wk Low/High | 31.25 / 58.46 |
| Volume | 713.43K |
| Avg Volume | 1.10M |
| Exchange | NASDAQ |
| Shares Outstanding | 88.22M |
| Market Cap | 4.60B |
| EPS | -1.60 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
10 Sectors That Will Profit Big-Time From Oil's Crash
Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...
Short Interest In Neurocrine Biosciences Increases 16%
The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 1,118,638 share increase in total short interest for Neurocrine Biosciences, Inc. , to 8,122,994, an increase of 15.97% since 05/31/2017.
Neurocrine Biosciences To Present At The Goldman Sachs 38th Annual Global Healthcare Conference
Live Audio Webcast Will be on June 15, 2017
Neurocrine Biosciences To Present At The Jefferies 2017 Global Healthcare Conference
Live Audio Webcast Will be on June 8, 2017
Biotech Movers: Inovio, Neurocrine, Alnylam
Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.
Neurocrine Announces Phase II Results Of VMAT2 Inhibitor INGREZZA® For Treatment Of Tourette Syndrome
Study Provides Clear Path Forward for Future Pivotal Studies
AbbVie Presents Pivotal Phase 3 Data On Investigational Treatment Elagolix At The World Congress On Endometriosis
- Primary and secondary efficacy and safety data to be presented from two pivotal Phase 3 studies evaluating the use of elagolix in endometriosis-associated pain
Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference
Live Audio Webcast Will be on May 17, 2017
Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2017 Results
Conference Call and Webcast Scheduled for Tuesday, May 9, 2017
Neurocrine Announces INGREZZA™ Long-Term Safety And Efficacy Data To Be Presented At The 2017 American Academy Of Neurology Annual Meeting
Additional results from largest ever clinical program in tardive dyskinesia to be highlighted as platform and poster presentations
Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin
Geopolitical concerns dominated market moves as banks kicked off earnings season.
U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil
Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.
Wall Street Closes Lower Amid Continued Global Worries
Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.
Stocks Fall as Wall Street Can't Shake Geopolitical Concerns
Stocks are lower on Wednesday as markets continue to grapple with geopolitical uncertainty.
Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents
The company's shares were up 24% ahead of market's open on an FDA approval.
Neurocrine Announces FDA Approval Of INGREZZA™ (valbenazine) Capsules As The First And Only Approved Treatment For Adults With Tardive Dyskinesia (TD) (with Multimedia)
Provides significant and rapid reduction in involuntary movements with simple once-daily dosing
Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug
The U.S. Food and Drug Administration granted Ingrezza a relatively clean label that does not include a black box safety warning against suicidality or depression.
Neurocrine Announces FDA Approval Of INGREZZA TM (valbenazine) Capsules As The First And Only Approved Treatment For Adults With Tardive Dyskinesia (TD)
Provides significant and rapid reduction in involuntary movements with simple once-daily dosing
AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding In Women With Uterine Fibroids
- Elagolix, with or without add-back therapy, showed effective and rapid reduction of heavy menstrual bleeding compared to placebo in women with uterine fibroids
Neurocrine Announces American Journal Of Psychiatry Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (valbenazine) For The Treatment Of Tardive Dyskinesia
- Phase III study conducted in patients with tardive dyskinesia shows significant and meaningful reduction in symptoms with INGREZZA
Neurocrine And BIAL Announce Exclusive North American Licensing Agreement For Opicapone
Expands Movement Disorder Franchise with Rights to Commercialize Late Stage Asset for Parkinson's Disease
Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen
Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday.
